✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals

Biofil Chemicals & Pharmaceuticals Ltd.

BIOFILCHEM

Market Cap
₹87 Cr.
P/E
156.11

Biofil Chemicals & Pharmaceuticals Ltd.

  • Biofil Chem & Pharma
  • Achyut Healthcare
  • Ind-Swift
FAQs on Biofil Chemicals & Pharmaceuticals Ltd. Shareprice

Biofil Chem & Pharma has given lower returns compared to its competitors.
Biofil Chem & Pharma has grown at ~10.31% over the last 2yrs while peers have grown at a median rate of 17.64%

Biofil Chem & Pharma is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Biofil Chem & Pharma is 156, while 3 year average PE is 159.
Also latest EV/EBITDA of Biofil Chem & Pharma is 102 while 3yr average is 93.09.

View FAQ's On Business
Growth Table
  • Biofil Chemicals & Pharmaceuticals Ltd.
  • Achyut Healthcare
  • Ind-Swift
Balance Sheet
  • Biofil Chemicals & Pharmaceuticals Ltd.
  • Achyut Healthcare
  • Ind-Swift
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Biofil Chemicals & Pharmaceuticals Ltd.
  • Achyut Healthcare
  • Ind-Swift
Cash Flow
  • Biofil Chemicals & Pharmaceuticals Ltd.
  • Achyut Healthcare
  • Ind-Swift
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Biofil Chemicals & Pharmaceuticals Ltd.
  • Achyut Healthcare
  • Ind-Swift
Quarterly Results
  • Biofil Chemicals & Pharmaceuticals Ltd.
  • Achyut Healthcare
  • Ind-Swift
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Biofil Chemicals & Pharmaceuticals Ltd. Financials

Balance sheet of Biofil Chem & Pharma is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Biofil Chem & Pharma is increasing.
Latest net debt of Biofil Chem & Pharma is ₹0.21 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹4.04 Crs.

The profit is oscillating.
The profit of Biofil Chem & Pharma is ₹0.56 Crs for TTM, ₹0.71 Crs for Mar 2024 and ₹0.56 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Biofil Chem & Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Accounts Receivable

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech